Gilead Sciences, Inc.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
The study of the 53 patients in the U.S., Europe and Canada who required respiratory support showed that about two-thirds benefited from the drug.
It was a very busy week for clinical trial news. Here’s a look.
Although the data hasn’t been released yet, analysts are making predictions based on what little they do know.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
Gilead Sciences and Second Genome forged a four-year strategic collaboration that will boost chances to discover and develop new targets and drug candidates for the treatment of inflammatory bowel disease through microbiome research.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir.
A day after it was announced remdesivir had received Orphan Drug designation for treatment of COVID-19 from the U.S. Food and Drug Administration, Gilead Sciences submitted a request for the regulatory agency to rescind that offer after an outcry was raised over the potential for exclusivity for the experimental pandemic treatment.
JOBS
IN THE PRESS